Application of acetylation of 16th lysine residue of histone H4 in diagnosis and treatment of placenta-derived diseases
The invention provides an application of acetylation of a 16th lysine residue of histone H4 in diagnosis and treatment of placenta-derived diseases, and relates to the technical field of biomedicine, the method comprises the following steps: detecting expression of acetylation of the 16th lysine residue of histone H4, and finding that expression of H4K16ac in placenta villus of a patient suffering from recurrent abortion is significantly reduced through experiments, so that the expression of H4K16ac in placenta villus of the patient suffering from recurrent abortion is significantly reduced. The purpose of diagnosing placenta-derived diseases can be achieved by specifically detecting the expression of H4K16ac. Meanwhile, the expression of CDX2 is promoted by improving the expression of H4K16ac, the pluripotency of the trophoblast stem cells is maintained, and H4K16ac provides a new action target for treating placenta-derived diseases and can realize the diagnosis and/or treatment of placenta-derived diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BI SHILEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117388504 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001106198 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001106198 | ||
| 003 | DE-627 | ||
| 005 | 20240322141313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001106198 | ||
| 035 | |a (EPA)CN117388504 | ||
| 035 | |a (EPA)89440357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BI SHILEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of acetylation of 16th lysine residue of histone H4 in diagnosis and treatment of placenta-derived diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 | ||
| 520 | |a The invention provides an application of acetylation of a 16th lysine residue of histone H4 in diagnosis and treatment of placenta-derived diseases, and relates to the technical field of biomedicine, the method comprises the following steps: detecting expression of acetylation of the 16th lysine residue of histone H4, and finding that expression of H4K16ac in placenta villus of a patient suffering from recurrent abortion is significantly reduced through experiments, so that the expression of H4K16ac in placenta villus of the patient suffering from recurrent abortion is significantly reduced. The purpose of diagnosing placenta-derived diseases can be achieved by specifically detecting the expression of H4K16ac. Meanwhile, the expression of CDX2 is promoted by improving the expression of H4K16ac, the pluripotency of the trophoblast stem cells is maintained, and H4K16ac provides a new action target for treating placenta-derived diseases and can realize the diagnosis and/or treatment of placenta-derived diseases. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG SHUANG |4 aut | |
| 700 | 0 | |a ZHANG LIZI |4 aut | |
| 700 | 0 | |a CHEN DUNJIN |4 aut | |
| 700 | 0 | |a WANG FENGCHAO |4 aut | |
| 700 | 0 | |a CHEN YONGJIE |4 aut | |
| 700 | 0 | |a HUANG LIJUN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89440357/publication/CN117388504A1?q=CN117388504 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||